ENA QUANTRIX 25 IgG at Lahore PCR Lab

Understanding the ENA QUANTRIX 25 IgG Test at Lahore PCR Lab

The ENA QUANTRIX 25 IgG test is a state-of-the-art, comprehensive multiplex line immunoassay designed for the simultaneous qualitative and semi-quantitative detection of 25 distinct IgG autoantibodies in human serum. This advanced diagnostic profile is utilized to identify autoantibodies targeting extractable nuclear antigens (ENAs) and other crucial cytoplasmic and nuclear cellular components. At Lahore PCR Lab in Lahore, Pakistan, this highly specialized panel serves as a cornerstone in the diagnostic workup of Systemic Autoimmune Rheumatic Diseases (SARD), offering clinicians unparalleled diagnostic depth from a single blood sample.

Autoimmune disorders occur when the body’s immune system mistakenly identifies self-proteins as foreign invaders, producing autoantibodies that attack healthy tissues. The ENA QUANTRIX 25 IgG panel evaluates a broad spectrum of these autoantibodies, providing critical insights into diseases such as Systemic Lupus Erythematosus (SLE), Sjögren’s Syndrome, Systemic Sclerosis (Scleroderma), Polymyositis, Dermatomyositis, Mixed Connective Tissue Disease (MCTD), and primary biliary cholangitis. By utilizing advanced multiplex line immunoassay technology, Lahore PCR Lab ensures high specificity and sensitivity, enabling rheumatologists and immunologists to formulate precise, individualized treatment strategies based on a patient’s unique autoantibody profile.

The clinical importance of this panel lies in its ability to differentiate between overlapping autoimmune syndromes. Many connective tissue diseases present with similar constitutional symptoms, such as joint pain, fatigue, and skin rashes. The ENA QUANTRIX 25 IgG test resolves this diagnostic ambiguity by identifying specific serological markers that are highly characteristic of individual diseases. For instance, the presence of anti-double-stranded DNA (dsDNA) or anti-Smith (Sm) antibodies is highly specific for SLE, while anti-Scl-70 and anti-CENP-B point toward different clinical phenotypes of systemic sclerosis. This detailed characterization is vital for predicting organ involvement, assessing prognosis, and monitoring disease progression over time.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy and prevent potential analytical interference, patients undergoing the ENA QUANTRIX 25 IgG test at Lahore PCR Lab should adhere to the following preparation guidelines:

• No Fasting Required: Fasting is generally not mandatory for this specific immunological assay. Patients may consume food and water normally prior to sample collection.
• Medication Review: It is essential to inform the ordering physician and the laboratory staff of all current medications, particularly corticosteroids, immunosuppressive agents, or biological therapies, as these can modulate antibody levels and influence test results.
• Hydration: Maintaining adequate hydration by drinking plenty of water before the procedure is highly recommended, as it facilitates easier venous access.
• Timing of the Test: While the test can be performed at any time of day, consistency in timing is beneficial if the test is being repeated to monitor antibody titers over time.
• Avoid Biotin Supplements: High doses of biotin (Vitamin B7) can interfere with certain immunoassay methodologies. It is advisable to consult your physician regarding the temporary suspension of biotin-containing supplements for 48 hours prior to blood collection.

During the Procedure

The ENA QUANTRIX 25 IgG test is performed on a standard venous blood sample. The procedure is conducted by highly trained phlebotomists at Lahore PCR Lab, adhering to strict aseptic techniques and international safety standards:

• Patient Positioning: The patient is comfortably seated in a phlebotomy chair, and the arm is positioned to expose the antecubital fossa (the inner elbow area).
• Vein Selection and Preparation: The phlebotomist applies a tourniquet above the selected site to make the veins more prominent. The skin is then thoroughly cleansed with an antiseptic swab (typically 70% isopropyl alcohol) and allowed to air dry.
• Venipuncture: A sterile, single-use needle is gently inserted into the selected vein. Blood is drawn into a serum separator tube (SST) or a plain red-top tube, depending on specific laboratory protocols.
• Post-Collection Care: Once the required volume of blood is collected, the needle is carefully withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze to prevent hematoma formation. A small adhesive bandage is then applied.
• Sample Processing: The collected blood sample is allowed to clot completely at room temperature. It is then centrifuged to separate the serum from the cellular components. The isolated serum is subsequently analyzed using the multiplex line immunoassay system, where it is exposed to 25 purified recombinant or native antigens immobilized on test strips.
• Duration and Experience: The entire venipuncture process takes less than five minutes. Patients may experience a mild, brief pinching sensation during needle insertion, but the procedure is generally well-tolerated with minimal discomfort.

When is an ENA QUANTRIX 25 IgG Performed?

Suspected Systemic Lupus Erythematosus (SLE)

Physicians frequently request the ENA QUANTRIX 25 IgG panel when a patient presents with clinical features suggestive of Systemic Lupus Erythematosus. Key clinical indications include a classic malar (butterfly) rash across the cheeks and nose, photosensitivity, unexplained persistent fever, alopecia, mouth ulcers, and migratory joint pain. Because SLE can affect multiple organ systems, including the kidneys, heart, and central nervous system, early and accurate diagnosis is paramount. The detection of specific autoantibodies within this 25-antigen panel, such as anti-dsDNA, anti-Sm, anti-Ribosomal P-protein, and anti-Histone antibodies, provides definitive diagnostic evidence that helps confirm SLE and assess the risk of lupus nephritis or neuropsychiatric involvement.

Evaluation of Sjögren’s Syndrome and Sicca Symptoms

Sjögren’s Syndrome is a chronic autoimmune disorder characterized by the progressive destruction of exocrine glands, primarily leading to severe dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). Patients may also experience systemic manifestations, including joint pain, fatigue, and peripheral neuropathy. When patients present with these debilitating sicca symptoms, clinicians order the ENA QUANTRIX 25 IgG test to screen for anti-SS-A (Ro60), anti-Ro52, and anti-SS-B (La) antibodies. The presence of these specific autoantibodies, particularly in combination, strongly supports a diagnosis of Sjögren’s Syndrome and helps differentiate it from non-autoimmune causes of dryness, such as medication side effects or age-related glandular atrophy.

Investigation of Systemic Sclerosis (Scleroderma) and Raynaud’s Phenomenon

Systemic Sclerosis is a complex connective tissue disease characterized by microvascular damage, immunological activation, and widespread fibrosis of the skin and internal organs. Clinicians suspect this condition in patients presenting with Raynaud’s phenomenon (color changes in fingers and toes in response to cold or stress), sclerodactyly (skin thickening of the fingers), and esophageal dysfunction. The ENA QUANTRIX 25 IgG panel is invaluable in these cases, as it detects autoantibodies highly specific to different subsets of systemic sclerosis, such as anti-Scl-70 (associated with diffuse cutaneous systemic sclerosis and interstitial lung disease), anti-CENP-B (associated with limited cutaneous systemic sclerosis and CREST syndrome), and anti-RNA Polymerase III, allowing for early risk stratification and targeted monitoring.

Diagnosis of Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Idiopathic inflammatory myopathies, including polymyositis and dermatomyositis, are characterized by chronic muscle inflammation leading to progressive, symmetrical proximal muscle weakness (e.g., difficulty rising from a chair or climbing stairs). Dermatomyositis is additionally accompanied by characteristic skin lesions, such as Gottron’s papules on the knuckles and a heliotrope rash around the eyes. When these symptoms are present, the ENA QUANTRIX 25 IgG test is performed to detect myositis-specific and myositis-associated autoantibodies, such as anti-Jo-1, anti-Mi-2, and anti-Ku. Identifying these antibodies not only confirms the diagnosis of inflammatory muscle disease but also helps predict clinical phenotypes, such as the presence of interstitial lung disease or an increased risk of underlying malignancy.

Assessment of Mixed Connective Tissue Disease (MCTD) and Overlap Syndromes

Mixed Connective Tissue Disease (MCTD) is a distinct clinical entity characterized by overlapping features of SLE, systemic sclerosis, and polymyositis, occurring in association with exceptionally high titers of anti-U1-RNP antibodies. Patients often present with a combination of Raynaud’s phenomenon, swollen hands, arthritis, and muscle weakness. Because the clinical presentation of MCTD can be highly variable and mimic other rheumatic diseases, the ENA QUANTRIX 25 IgG panel is crucial. It simultaneously evaluates anti-U1-RNP alongside 24 other antigens, enabling physicians to clearly distinguish MCTD from other SARDs or overlap syndromes, thereby guiding appropriate therapeutic interventions and prognostic assessments.

What Does an ENA QUANTRIX 25 IgG Detect?

The ENA QUANTRIX 25 IgG panel at Lahore PCR Lab is designed to detect a comprehensive array of autoantibodies, each associated with specific clinical conditions and pathological processes:

• Anti-dsDNA: Highly specific for Systemic Lupus Erythematosus (SLE); strongly associated with lupus nephritis and disease activity.
• Anti-Nucleosome: A sensitive marker for SLE, often appearing in patients with active renal disease.
• Anti-Histone: Strongly associated with Drug-Induced Lupus Erythematosus (DILE), as well as idiopathic SLE.
• Anti-Ribosomal P-Protein: Highly specific for SLE; associated with neuropsychiatric lupus, lupus hepatitis, and nephritis.
• Anti-Sm (Smith): Pathognomonic for SLE; included in the classification criteria for the disease.
• Anti-U1-RNP (70 kDa/A/C): The defining serological marker for Mixed Connective Tissue Disease (MCTD) when present in high titers.
• Anti-SS-A / Ro60: Commonly found in Sjögren’s Syndrome, SLE, and neonatal lupus (associated with congenital heart block).
• Anti-Ro52 (TRIM21): Frequently detected in Sjögren’s Syndrome, systemic sclerosis, and myositis; associated with interstitial lung disease.
• Anti-SS-B / La: Highly specific for Sjögren’s Syndrome, almost always occurring in conjunction with anti-SS-A antibodies.
• Anti-Scl-70 (Topoisomerase I): Specific for diffuse cutaneous Systemic Sclerosis; strongly associated with pulmonary fibrosis.
• Anti-CENP-A / CENP-B (Centromere): Associated with limited cutaneous Systemic Sclerosis and CREST syndrome; portends a lower risk of severe pulmonary fibrosis.
• Anti-RNA Polymerase III (RP11/RP155): Associated with diffuse systemic sclerosis, rapid skin involvement, and increased risk of scleroderma renal crisis.
• Anti-Jo-1 (Histidyl-tRNA synthetase): The most common myositis-specific antibody; associated with Antisynthetase Syndrome (myositis, interstitial lung disease, arthritis, Raynaud’s, and mechanic’s hands).
• Anti-Mi-2 (NuRD complex): Highly specific for Dermatomyositis; generally associated with a favorable response to therapy and a good prognosis.
• Anti-Ku: Associated with overlap syndromes involving systemic sclerosis, polymyositis, and SLE.
• Anti-PM-Scl100 / PM-Scl75: Found in patients with polymyositis-scleroderma overlap syndrome.
• Anti-PCNA (Proliferating Cell Nuclear Antigen): A rare but highly specific marker for SLE, sometimes associated with severe nephritis.
• Anti-AMA-M2 (Antimitochondrial Antibody): The hallmark serological marker for Primary Biliary Cholangitis (PBC), an autoimmune liver disease.
• Anti-DFS70: Often found in healthy individuals or those with non-systemic autoimmune conditions; a positive result in the absence of other SARD-specific antibodies helps rule out systemic rheumatic diseases.
• Anti-gp210: A specific marker for Primary Biliary Cholangitis, associated with a more progressive disease course.
• Anti-sp100: Another highly specific marker for Primary Biliary Cholangitis, aiding in diagnosis when AMA-M2 is negative.
• Anti-PL-7 (Threonyl-tRNA synthetase): Associated with Antisynthetase Syndrome and severe interstitial lung disease.
• Anti-PL-12 (Alanyl-tRNA synthetase): Associated with Antisynthetase Syndrome, often presenting with early lung involvement.
• Anti-Ro60: Specifically targets the 60 kDa Ro protein, crucial for diagnosing primary Sjögren’s syndrome and cutaneous lupus.
• Anti-SRP (Signal Recognition Particle): Associated with necrotizing autoimmune myopathy, characterized by severe, rapidly progressive muscle weakness.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely diagnostic results are critical for alleviating patient anxiety and enabling clinicians to initiate prompt therapeutic interventions. The ENA QUANTRIX 25 IgG test involves a complex, multi-step multiplex line immunoassay that requires meticulous calibration, incubation, and quality control verification to ensure absolute accuracy. Consequently, the standard turnaround time for this comprehensive panel is typically 3 to 5 working days from the time of sample collection.

Once the analysis is complete, the results undergo a rigorous multi-level review process by our consultant pathologists to ensure clinical validity. Patients and their referring physicians are immediately notified via SMS and email once the report is finalized. Reports can be securely accessed and downloaded online through the official Lahore PCR Lab web portal or mobile application, eliminating the need for a physical visit to the lab. Additionally, hard copies of the reports can be collected directly from our main diagnostic center or delivered via our dedicated courier service upon request.

ENA QUANTRIX 25 IgG Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-dsDNA IgG	Negative / Non-reactive	Positive (Associated with SLE and active lupus nephritis)
Anti-Sm IgG	Negative / Non-reactive	Positive (Highly specific for Systemic Lupus Erythematosus)
Anti-U1-RNP IgG	Negative / Non-reactive	Positive (High titers indicate Mixed Connective Tissue Disease)
Anti-SS-A (Ro60) / Ro52 IgG	Negative / Non-reactive	Positive (Associated with Sjögren’s Syndrome, SLE, and neonatal lupus)
Anti-SS-B (La) IgG	Negative / Non-reactive	Positive (Highly suggestive of Sjögren’s Syndrome)
Anti-Scl-70 IgG	Negative / Non-reactive	Positive (Associated with diffuse Systemic Sclerosis and lung fibrosis)
Anti-CENP-B IgG	Negative / Non-reactive	Positive (Associated with limited Systemic Sclerosis / CREST syndrome)
Anti-Jo-1 IgG	Negative / Non-reactive	Positive (Indicates Antisynthetase Syndrome / Polymyositis)
Anti-AMA-M2 IgG	Negative / Non-reactive	Positive (Highly specific for Primary Biliary Cholangitis)
Anti-DFS70 IgG	Negative / Non-reactive	Positive (Often isolated in healthy individuals, helps rule out SARD)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for ENA QUANTRIX 25 IgG?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists, clinical immunologists, and medical technologists specializing in advanced serological assays.
• Patient-Focused Care: We prioritize patient comfort, safety, and confidentiality throughout the diagnostic journey, ensuring a seamless and supportive experience.
• Quality Diagnostic Services: Lahore PCR Lab adheres to stringent internal and external quality control protocols, ensuring the highest level of analytical precision and reproducibility.
• Professional Reporting: Our diagnostic reports are comprehensive, clearly structured, and include detailed clinical interpretations to assist referring physicians in clinical decision-making.
• Modern Diagnostic Approach: We utilize state-of-the-art multiplex line immunoassay technology, allowing for the simultaneous detection of 25 autoantibodies from a single specimen.
• Comfortable Environment: Our diagnostic centers in Lahore are designed to provide a clean, hygienic, and welcoming environment for all patients.
• Convenient Location: Strategically located in Lahore, Pakistan, our laboratory is easily accessible, offering ample parking and convenient operating hours.
• Commitment to Accurate Diagnosis: We are dedicated to delivering timely, evidence-based diagnostic insights that empower patients and clinicians to manage complex autoimmune conditions effectively.